COGT
NASDAQCogent Biosciences Inc.
Price$36.84+0.89 (+2.48%)
01:30 PM07:45 PM
News · 26 weeks55-33%
2025-11-022026-04-26
Mix1890d
- Other10(56%)
- SEC Filings5(28%)
- Insider2(11%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Cogent Biosciences Inc.DEFA14A - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECSEC Form DEF 14A filed by Cogent Biosciences Inc.DEF 14A - Cogent Biosciences, Inc. (0001622229) (Filer)
- PRCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingWALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the results from the Phase 3 PEAK trial have been selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, May 29-June 2, 2026. The presentation will feature data from the positive trial of bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. Top line results were reported in November 2025, and t
- PRCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on Cogent's brain penetrant ErbB2 inhibitor, CGT4255, with evidence of synergistic activity in combination with HER2 ADCs for resistant patients WALTHAM, Mass. and BOULDER, Colo., April 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that preclinical data from the Company's KRAS and ErbB2 pipeline programs will be presented during poster se
- INSIDERSEC Form 4 filed by Ferrante Karen Jean4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- PRCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination demonstrated 16.5 month mPFS and 46% ORR in imatinib-resistant GIST patients, dramatically improving upon the current standard of care WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastin
- INSIDERSEC Form 4 filed by Fairmount Funds Management Llc4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
- ANALYSTJefferies resumed coverage on Cogent BiosciencesJefferies resumed coverage of Cogent Biosciences with a rating of Buy
- PRCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues.Clinical results from the pivotal SUMMIT trial wit
- PRCogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingBezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalizationStrong evidence of bezuclastinib's potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinica
- SECSEC Form S-8 filed by Cogent Biosciences Inc.S-8 - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECSEC Form 10-K filed by Cogent Biosciences Inc.10-K - Cogent Biosciences, Inc. (0001622229) (Filer)
- SECCogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
- PRCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsSUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial position with $901 million sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company f
- PRCogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual MeetingWALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2, 2026. In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on posi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
- PRCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. "We are excited to announce this Breakthrough Therapy Designat
- INSIDERDirector Fairmount Funds Management Llc sold $127,400,000 worth of shares (3,500,000 units at $36.40) (SEC Form 4)4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- PRCogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib - Cogent is expected to initiate the RTOR process immediately; completion of the PEAK NDA submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its Ne
- PRCogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies PortfolioNew Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 yearsClinical data presentations from all three pivotal trials, PEAK, SUMMIT and APEX, expected at major medical meetings in 1H 2026Investigational New Drug (IND) applications expected in 2026 for potentially best-in-class pan-KRAS(ON) and selective JAK2 V617F inhibitorsStrong financial position with ~$900 million cash to begin 2026, sufficient to fund commercial launches and operations well into 2028Company to present at the 44th Annual J.P.
- PRCogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Bios
- INSIDERSEC Form 4 filed by Director Ferrante Karen Jean4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- INSIDERChief Financial Officer Green John L. sold $2,978,360 worth of shares (77,000 units at $38.68), decreasing direct ownership by 37% to 131,834 units (SEC Form 4)4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
- INSIDERChief Medical Officer Sachs Jessica sold $3,198,245 worth of shares (82,642 units at $38.70), decreasing direct ownership by 38% to 133,938 units (SEC Form 4)4 - Cogent Biosciences, Inc. (0001622229) (Issuer)